Kim, C-Y
(1Research Laboratories of Dong-A Pharmaceutical Co., Ltd, Kyunggi-Do, Korea)
,
Jeong, M
(1Research Laboratories of Dong-A Pharmaceutical Co., Ltd, Kyunggi-Do, Korea)
,
Mushiake, H
(1Research Laboratories of Dong-A Pharmaceutical Co., Ltd, Kyunggi-Do, Korea)
,
Kim, B-M
(1Research Laboratories of Dong-A Pharmaceutical Co., Ltd, Kyunggi-Do, Korea)
,
Kim, W-B
(1Research Laboratories of Dong-A Pharmaceutical Co., Ltd, Kyunggi-Do, Korea)
,
Ko, J P
(2Genenmed Inc., Jongno-Gu, Seoul, Korea)
,
Kim, M-H
(3Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA)
,
Kim, M
(3Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA)
,
Kim, T-H
(4Research Center for Resistant Cells and Department of Biochemistry, Chosun University School of Medicine, Dong-Gu, Gwangju, Korea)
,
Robbins, P D
(5Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA)
,
Billiar, T R
(3Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA)
,
Seol, D-W
(3Department of Surgery, University of Pitts)
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF family, is a type II transmembrane cytokine molecule. Soluble TRAIL has been shown to induce apoptosis in a wide variety of cancer cells in vitro and to suppress tumor growth specifically without damaging norm...
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF family, is a type II transmembrane cytokine molecule. Soluble TRAIL has been shown to induce apoptosis in a wide variety of cancer cells in vitro and to suppress tumor growth specifically without damaging normal cells and tissues in vivo. In our previous report, we have demonstrated that an artificial gene encoding the polypeptide composed of the three functional elements (a secretion signal, a trimerization domain and an apoptosis-inducing moiety of TRAIL gene sequence) expresses and secretes highly apoptotic trimeric TRAIL into the culture supernatant. Here, as an approach to TRAIL-based cancer gene therapy, we developed an adenoviral vector delivering the gene that encodes our secretable trimeric TRAIL (stTRAIL). This adenovirus (Ad-stTRAIL) potently induced apoptosis in vitro in cancer cell lines such as HeLa, MDA-MB-231, A549, HCT116 and U-87MG. In an animal xenograft tumor model bearing a human glioma cell line U-87MG, intratumoral delivery of Ad-stTRAIL dramatically suppressed tumor growth without showing detectable adverse side effects. Histological analysis revealed that Ad-stTRAIL suppresses tumor growth by inducing apoptotic cell death. Contrary to the known rapid clearance of systemically delivered TRAIL protein from the blood circulation, stTRAIL expressed by Ad-stTRAIL in tumor tissues persisted for more than 4 days. In a comparison of tumor suppressor activity between Ad-stTRAIL and Ad-flTRAIL (delivering the full-length TRAIL gene) after mixing infected cells with uninfected cells and implanting these mixed cells in nude mice, Ad-stTRAIL showed higher tumor suppressor activity than that of Ad-flTRAIL. Our data reveal that a gene therapy using Ad-stTRAIL has a promising potential to treat human cancers including gliomas.Gene Therapy (2006) 13, 330–338. doi:10.1038/sj.gt.3302658; published online 29 September 2005
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF family, is a type II transmembrane cytokine molecule. Soluble TRAIL has been shown to induce apoptosis in a wide variety of cancer cells in vitro and to suppress tumor growth specifically without damaging normal cells and tissues in vivo. In our previous report, we have demonstrated that an artificial gene encoding the polypeptide composed of the three functional elements (a secretion signal, a trimerization domain and an apoptosis-inducing moiety of TRAIL gene sequence) expresses and secretes highly apoptotic trimeric TRAIL into the culture supernatant. Here, as an approach to TRAIL-based cancer gene therapy, we developed an adenoviral vector delivering the gene that encodes our secretable trimeric TRAIL (stTRAIL). This adenovirus (Ad-stTRAIL) potently induced apoptosis in vitro in cancer cell lines such as HeLa, MDA-MB-231, A549, HCT116 and U-87MG. In an animal xenograft tumor model bearing a human glioma cell line U-87MG, intratumoral delivery of Ad-stTRAIL dramatically suppressed tumor growth without showing detectable adverse side effects. Histological analysis revealed that Ad-stTRAIL suppresses tumor growth by inducing apoptotic cell death. Contrary to the known rapid clearance of systemically delivered TRAIL protein from the blood circulation, stTRAIL expressed by Ad-stTRAIL in tumor tissues persisted for more than 4 days. In a comparison of tumor suppressor activity between Ad-stTRAIL and Ad-flTRAIL (delivering the full-length TRAIL gene) after mixing infected cells with uninfected cells and implanting these mixed cells in nude mice, Ad-stTRAIL showed higher tumor suppressor activity than that of Ad-flTRAIL. Our data reveal that a gene therapy using Ad-stTRAIL has a promising potential to treat human cancers including gliomas.Gene Therapy (2006) 13, 330–338. doi:10.1038/sj.gt.3302658; published online 29 September 2005
참고문헌 (39)
Science A Ashkenazi 281 1305 1998 10.1126/science.281.5381.1305 Ashkenazi A, Dixit VM . Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
J Biol Chem M MacFarlane 272 25417 1997 10.1074/jbc.272.41.25417 MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES . Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272: 25417-25420.
Science G Pan 276 111 1997 10.1126/science.276.5309.111 Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113.
Science JP Sheridan 277 818 1997 10.1126/science.277.5327.818 Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.
Cell H Hsu 81 495 1995 10.1016/0092-8674(95)90070-5 Hsu H, Xiong J, Goeddel DV . The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995; 81: 495-504.
Cell H Hsu 84 299 1996 10.1016/S0092-8674(00)80984-8 Hsu H, Shu HB, Pan MG, Goeddel DV . TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84: 299-308.
Cell ZG Liu 87 565 1996 10.1016/S0092-8674(00)81375-6 Liu ZG, Hsu H, Goeddel DV, Karin M . Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996; 87: 565-576.
Immunity MA Kelliher 8 297 1998 10.1016/S1074-7613(00)80535-X Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P . The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8: 297-303.
J Biol Chem MP Boldin 270 7795 1995 10.1074/jbc.270.14.7795 Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D . A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270: 7795-7798.
Cell AM Chinnaiyan 81 505 1995 10.1016/0092-8674(95)90071-3 Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM . FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.
Curr Biol P Juo 8 1001 1998 10.1016/S0960-9822(07)00420-4 Juo P, Kuo CJ, Yuan J, Blenis J . Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol 1998; 8: 1001-1008.
Immunity SR Wiley 3 673 1995 10.1016/1074-7613(95)90057-8 Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
J Biol Chem RM Pitti 271 12687 1996 10.1074/jbc.271.22.12687 Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A . Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690.
J Clin Invest A Ashkenazi 104 155 1999 10.1172/JCI6926 Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
Nat Med H Walczak 5 157 1999 10.1038/5517 Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
Nature J Ogasawara 364 806 1993 10.1038/364806a0 Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
J Exp Med PR Galle 182 1223 1995 10.1084/jem.182.5.1223 Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223-1230.
Immunity SS Cha 11 253 1999 10.1016/S1074-7613(00)80100-4 Cha SS, Kim MS, Choi YH, Sung BJ, Shin NK, Shin HC et al. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 1999; 11: 253-261.
Mol Cell SG Hymowitz 4 563 1999 10.1016/S1097-2765(00)80207-5 Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999; 4: 563-571.
Biochemistry SG Hymowitz 39 633 2000 10.1021/bi992242l Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000; 39: 633-640.
Biochem J D Trabzuni 350 Part 2 505 2000 10.1042/bj3500505 Trabzuni D, Famulski KS, Ahmad M . Functional analysis of tumour necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochem J 2000; 350 (Part 2): 505-510.
Biochem Biophys Res Commun MH Kim 321 930 2004 10.1016/j.bbrc.2004.07.046 Kim MH, Billiar TR, Seol DW . The secretable form of trimeric TRAIL, a potent inducer of apoptosis. Biochem Biophys Res Commun 2004; 321: 930-935.
Cancer Gene Ther D Jacob 12 109 2005 10.1038/sj.cgt.7700773 Jacob D, Davis JJ, Zhang L, Zhu H, Teraishi F, Fang B . Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther 2005; 12: 109-115.
FEBS Lett JB Denault 379 113 1996 10.1016/0014-5793(95)01487-X Denault JB, Leduc R . Furin/PACE/SPC1: a convertase involved in exocytic and endocytic processing of precursor proteins. FEBS Lett 1996; 379: 113-116.
FEBS Lett J Rieger 427 124 1998 10.1016/S0014-5793(98)00409-8 Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M . APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett 1998; 427: 124-128.
Brain Pathol JH Song 13 539 2003 10.1111/j.1750-3639.2003.tb00484.x Song JH, Song DK, Pyrzynska B, Petruk KC, Van Meir EG, Hao C . TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 2003; 13: 539-553.
Biochem Biophys Res Commun W Roth 265 479 1999 10.1006/bbrc.1999.1693 Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999; 265: 479-483.
Surg Oncol Clin N Am DK Frank 11 589 2002 10.1016/S1055-3207(02)00021-2 Frank DK . Gene therapy for head and neck cancer. Surg Oncol Clin N Am 2002; 11: 589-606, vi-vii.
Drugs W Walther 60 249 2000 10.2165/00003495-200060020-00002 Walther W, Stein U . Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000; 60: 249-271.
Hum Gene Ther SL Eck 12 97 2001 10.1089/104303401451013 Eck SL, Alavi JB, Judy K, Phillips P, Alavi A, Hackney D et al. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial. Hum Gene Ther 2001; 12: 97-113.
Mol Ther H Zhu 9 666 2004 10.1016/j.ymthe.2004.02.007 Zhu H, Zhang L, Huang X, Davis JJ, Jacob DA, Teraishi F et al. Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther 2004; 9: 666-673.
J Virol S Hardy 71 1842 1997 10.1128/jvi.71.3.1842-1849.1997 Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML . Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997; 71: 1842-1849.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.